SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (date of earliest event reported) January 14, 2004
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| 000-23265 | 94-3267443 | |
| (Commission file Number) | (IRS Employer ID Number) |
8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina | 27615 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (919) 862-1000
| Item 5. | Other Events and Regulation FD Disclosure |
On January 14, 2004, Salix Pharmaceuticals, Ltd. issued a press release announcing the appointment of William P. Keane to the Company’s Board of Directors. A copy of this press release is attached.
| Item 7. | Financial Statements and Exhibits. |
| (c) | Exhibits |
| Exhibit No. | Description | |
99.1 | Press release dated January 14, 2004 of Salix Pharmaceuticals, Ltd., announcing the appointment of William P. Keane to the Company’s Board of Directors. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SALIX PHARMACEUTICALS, LTD. | ||||||||
| Date: | January 14, 2004 | By: | /s/ Adam C. Derbyshire | |||||
Adam C. Derbyshire Senior Vice President and Chief Financial Officer
| ||||||||
